Sitafloxacin hydrate
Modify Date: 2024-01-11 12:08:40
Sitafloxacin hydrate structure
|
Common Name | Sitafloxacin hydrate | ||
|---|---|---|---|---|
| CAS Number | 163253-35-8 | Molecular Weight | 436.84 | |
| Density | N/A | Boiling Point | 629.2ºC at 760mmHg | |
| Molecular Formula | C19H18ClF2N3O3.3/2H2O | Melting Point | 145-147°C (dec.) | |
| MSDS | N/A | Flash Point | 334.3ºC | |
Use of Sitafloxacin hydrateSitafloxacin Hydrate is a new-generation, broad-spectrum oral fluoroquinolone antibiotic.Target: AntibacterialSitafloxacin Hydrate, a new-generation, broad-spectrum oral fluoroquinolone that is very active against many Gram-positive, Gram-negative and anaerobic clinical isolates, including strains resistant to other fluoroquinolones, was recently approved in Japan for the treatment of respiratory and urinary tract infections [1]. In terms of clinical efficacy, oral sitafloxacin was noninferior to oral levofloxacin in the treatment of community-acquired pneumonia or an infectious exacerbation of chronic respiratory tract disease, noninferior to oral tosufloxacin in the treatment of community-acquired pneumonia, and noninferior to oral levofloxacin in the treatment of complicated urinary tract infections, according to the results of randomized, double-blind, multicentre, noninferiority trials. Noncomparative studies demonstrated the efficacy of oral sitafloxacin in otorhinolaryngological infections, urethritis in men, C. trachomatis-associated cervicitis in women and odontogenic infections [2]. |
| Name | Sitafloxacin Sesquihydrate |
|---|---|
| Synonym | More Synonyms |
| Description | Sitafloxacin Hydrate is a new-generation, broad-spectrum oral fluoroquinolone antibiotic.Target: AntibacterialSitafloxacin Hydrate, a new-generation, broad-spectrum oral fluoroquinolone that is very active against many Gram-positive, Gram-negative and anaerobic clinical isolates, including strains resistant to other fluoroquinolones, was recently approved in Japan for the treatment of respiratory and urinary tract infections [1]. In terms of clinical efficacy, oral sitafloxacin was noninferior to oral levofloxacin in the treatment of community-acquired pneumonia or an infectious exacerbation of chronic respiratory tract disease, noninferior to oral tosufloxacin in the treatment of community-acquired pneumonia, and noninferior to oral levofloxacin in the treatment of complicated urinary tract infections, according to the results of randomized, double-blind, multicentre, noninferiority trials. Noncomparative studies demonstrated the efficacy of oral sitafloxacin in otorhinolaryngological infections, urethritis in men, C. trachomatis-associated cervicitis in women and odontogenic infections [2]. |
|---|---|
| Related Catalog | |
| References |
[2]. Keating, G.M., Sitafloxacin: in bacterial infections. Drugs, 2011. 71(6): p. 731-44. |
| Boiling Point | 629.2ºC at 760mmHg |
|---|---|
| Melting Point | 145-147°C (dec.) |
| Molecular Formula | C19H18ClF2N3O3.3/2H2O |
| Molecular Weight | 436.84 |
| Flash Point | 334.3ºC |
| PSA | 97.79000 |
| LogP | 3.40360 |
| Vapour Pressure | 1.06E-16mmHg at 25°C |
| Storage condition | Hygroscopic, -20°C Freezer, Under Inert Atmosphere |
| Sitafloxacin hydrate |
| 7-[(7S)-7-Amino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid hydrate (1:1) |
| DU 6859A,DU 6859,DU-6859 |
| 3-Quinolinecarboxylic acid, 7-[(7S)-7-amino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-4-oxo-, hydrate (1:1) |
| Sitafloxacin |
| Sitafloxacin (hydrate) |